ES2931530T3 - Método para generar progenitores de células T - Google Patents

Método para generar progenitores de células T Download PDF

Info

Publication number
ES2931530T3
ES2931530T3 ES18704551T ES18704551T ES2931530T3 ES 2931530 T3 ES2931530 T3 ES 2931530T3 ES 18704551 T ES18704551 T ES 18704551T ES 18704551 T ES18704551 T ES 18704551T ES 2931530 T3 ES2931530 T3 ES 2931530T3
Authority
ES
Spain
Prior art keywords
cells
alpha
cell
tnf
vitro method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18704551T
Other languages
English (en)
Spanish (es)
Inventor
Isabelle Andre
Marina Cavazzana
Kuiying Ma
John Tchen
Tayebeh-Shabi Soheili
Moirangthem Ranjita Devi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondation Imagine Inst Des Maladies Genetiques
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Cité
Original Assignee
Fondation Imagine Inst Des Maladies Genetiques
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Cité
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondation Imagine Inst Des Maladies Genetiques, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Université Paris Cité filed Critical Fondation Imagine Inst Des Maladies Genetiques
Application granted granted Critical
Publication of ES2931530T3 publication Critical patent/ES2931530T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
ES18704551T 2017-02-13 2018-02-12 Método para generar progenitores de células T Active ES2931530T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305161 2017-02-13
PCT/EP2018/053406 WO2018146297A1 (en) 2017-02-13 2018-02-12 Method for generating t cells progenitors

Publications (1)

Publication Number Publication Date
ES2931530T3 true ES2931530T3 (es) 2022-12-30

Family

ID=58185453

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18704551T Active ES2931530T3 (es) 2017-02-13 2018-02-12 Método para generar progenitores de células T

Country Status (17)

Country Link
US (5) US20200046767A1 (enExample)
EP (2) EP3580330B1 (enExample)
JP (2) JP7164798B2 (enExample)
KR (1) KR102666158B1 (enExample)
CN (1) CN110506110B (enExample)
AU (1) AU2018217404B2 (enExample)
BR (1) BR112019016672A8 (enExample)
CA (1) CA3053294A1 (enExample)
DK (1) DK3580330T3 (enExample)
ES (1) ES2931530T3 (enExample)
HU (1) HUE060548T2 (enExample)
IL (1) IL268641B2 (enExample)
MA (1) MA47541A (enExample)
PL (1) PL3580330T3 (enExample)
PT (1) PT3580330T (enExample)
WO (1) WO2018146297A1 (enExample)
ZA (1) ZA201905470B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T
CA3077344A1 (en) * 2017-09-29 2019-04-04 Regents Of The University Of Minnesota Methods of making, expanding, and using a human progenitor t cell
EP3700334B1 (en) 2017-10-27 2026-04-08 Immunebridge Inc. Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
EP3847243A1 (en) * 2018-09-07 2021-07-14 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
WO2020223517A1 (en) * 2019-05-01 2020-11-05 Transfusion Health, Llc Methods of making oligopotent and unipotent precursors
CA3144640A1 (en) * 2019-06-24 2020-12-30 Children's Hospital Los Angeles Bcl11b overexpression to enhance human thymopoiesis and t cell function
EP4058562A4 (en) * 2019-11-14 2023-12-20 Zandstra, Peter William MEDIA FORMULATIONS AND PROCESSES FOR PRODUCING PROGENITOR T CELLS
WO2021200901A1 (ja) * 2020-03-31 2021-10-07 国立大学法人京都大学 Ｔ前駆細胞の製造方法
CN116615461A (zh) 2020-11-30 2023-08-18 醣基生医股份有限公司 用于富集细胞的抗体
CA3209946A1 (en) * 2021-03-05 2022-09-09 Matthew Angel Engineered immune cell therapies
EP4347793A1 (en) * 2021-05-25 2024-04-10 Universiteit Gent Generating t cell precursors via agonizing tumor necrosis factor receptor 2
US20260152721A1 (en) 2021-11-04 2026-06-04 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt
KR20250150555A (ko) 2023-01-27 2025-10-20 노치 테라퓨틱스 (캐나다) 인크. 줄기세포/전구세포로부터 t 세포 계통 모집단을 생성하는 방법
KR20250152088A (ko) * 2023-02-22 2025-10-22 메이라지티엑스 셀 테라피스 흉선 재생 방법
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
CN121969764A (zh) * 2024-08-29 2026-05-01 京东方科技集团股份有限公司 引物设计、疾病分型诊断方法及装置、组合物、试剂盒及其用途
CN119709836B (zh) * 2024-12-21 2025-08-08 湖南农业大学 OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO1999028486A1 (en) 1997-12-04 1999-06-10 Duke University Methods of isolating and using cd7+cd34-lin-hematopoietic cells
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
CA2737193A1 (en) 2008-09-12 2010-03-18 Universidade Federal De Sao Paulo - Unifesp Ischemic tissue cell therapy
US8772028B2 (en) * 2008-11-07 2014-07-08 Sunnybrook Health Sciences Centre CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
EP3590520B1 (en) 2010-04-09 2021-12-29 Fred Hutchinson Cancer Research Center Compositions for providing hematopoietic function without hla matching
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013086436A1 (en) * 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US20150352180A1 (en) 2013-01-11 2015-12-10 The Trustee Of The University Of Pennsylvania Notch Ligand Bound Biocompatible Substrates And Their Use In Bone Formation
EP3027755B1 (en) * 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
JP6661544B2 (ja) * 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
WO2016039933A1 (en) 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
US11555207B2 (en) * 2015-06-17 2023-01-17 The Uab Research Foundation CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
US12076342B2 (en) 2016-04-08 2024-09-03 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T

Also Published As

Publication number Publication date
US20230293586A1 (en) 2023-09-21
AU2018217404B2 (en) 2024-03-28
US11638723B2 (en) 2023-05-02
PT3580330T (pt) 2022-12-06
AU2018217404A1 (en) 2019-09-05
BR112019016672A8 (pt) 2022-11-22
US11642376B2 (en) 2023-05-09
CA3053294A1 (en) 2018-08-16
US20210169935A1 (en) 2021-06-10
IL268641B1 (en) 2024-06-01
WO2018146297A1 (en) 2018-08-16
US20200390817A1 (en) 2020-12-17
JP7164798B2 (ja) 2022-11-02
RU2019125600A (ru) 2021-03-15
JP2020513844A (ja) 2020-05-21
PL3580330T3 (pl) 2023-01-16
EP4067482A1 (en) 2022-10-05
AU2018217404A2 (en) 2019-09-19
US20210169934A1 (en) 2021-06-10
CN110506110A (zh) 2019-11-26
EP3580330B1 (en) 2022-08-31
RU2019125600A3 (enExample) 2021-11-03
ZA201905470B (en) 2024-12-18
US11426430B2 (en) 2022-08-30
HUE060548T2 (hu) 2023-03-28
IL268641B2 (en) 2024-10-01
EP3580330A1 (en) 2019-12-18
BR112019016672A2 (pt) 2020-04-14
MA47541A (fr) 2019-12-18
IL268641A (en) 2019-10-31
KR102666158B1 (ko) 2024-05-16
KR20190117550A (ko) 2019-10-16
CN110506110B (zh) 2024-09-06
DK3580330T3 (da) 2022-12-05
JP2022185024A (ja) 2022-12-13
US20200046767A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
US11638723B2 (en) Method for generating T cells progenitors
Heipertz et al. Current perspectives on “off-the-shelf” allogeneic NK and CAR-NK cell therapies
ES2991327T3 (es) Proteína de fusión para la utilización en el tratamiento de la enfermedad EHCI
ES2914082T3 (es) Procedimiento de generación de progenitores de células T
Kremer et al. Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors
CA2170980A1 (en) Genetically modified human hematopoietic stem cells and their progeny
IL293075A (en) Bioengineered thymus organoids from pluripotent human stem cells
Zhou et al. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia
HK40081656A (en) Method for generating t cells progenitors
CN118510525A (zh) 产生nk细胞的方法
RU2797260C2 (ru) Способ получения предшественников т-клеток
HK40017982B (en) Method for generating t cells progenitors
HK40017982A (en) Method for generating t cells progenitors
WO2025220666A1 (en) Cytotoxic Lymphocytes Expressing Variable Region-Deleted T Cell Receptors
Carretta Modeling of MLL-AF9-rearranged pediatric leukemia: Identification of mechanisms and potential targets
WO2023240182A1 (en) Disruption of kdm4a in t cells to enhance immunotherapy
Guerrettaz Aging-associated changes in B-lymphopoiesis
Kreuzaler The Potential (therapeutic) Role of BAFF, FLT3L and IL-2 in Immune Disorders